- Home
- KINS vs CYBN Comparison
KINS vs CYBN Comparison
Compare KINS & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KINS
- CYBN
- Stock Information
- Founded
- KINS 1886
- CYBN 2019
- Country
- KINS United States
- CYBN Canada
- Employees
- KINS N/A
- CYBN N/A
- Industry
- KINS Property-Casualty Insurers
- CYBN Pharmaceuticals and Biotechnology
- Sector
- KINS Finance
- CYBN Health Care
- Exchange
- KINS Nasdaq
- CYBN Nasdaq
- Market Cap
- KINS 189.6M
- CYBN 176.5M
- IPO Year
- KINS N/A
- CYBN N/A
- Fundamental
- Price
- KINS $14.75
- CYBN $6.22
- Analyst Decision
- KINS
- CYBN Strong Buy
- Analyst Count
- KINS 0
- CYBN 3
- Target Price
- KINS N/A
- CYBN $85.00
- AVG Volume (30 Days)
- KINS 140.2K
- CYBN 717.1K
- Earning Date
- KINS 10-28-2025
- CYBN 11-12-2025
- Dividend Yield
- KINS 1.36%
- CYBN N/A
- EPS Growth
- KINS 325.10
- CYBN N/A
- EPS
- KINS 2.04
- CYBN N/A
- Revenue
- KINS $183,702,376.00
- CYBN N/A
- Revenue This Year
- KINS $41.35
- CYBN N/A
- Revenue Next Year
- KINS $12.33
- CYBN N/A
- P/E Ratio
- KINS $7.23
- CYBN N/A
- Revenue Growth
- KINS 28.36
- CYBN N/A
- 52 Week Low
- KINS $8.45
- CYBN $4.81
- 52 Week High
- KINS $22.40
- CYBN $13.88
- Technical
- Relative Strength Index (RSI)
- KINS 52.30
- CYBN 47.09
- Support Level
- KINS $14.23
- CYBN $5.93
- Resistance Level
- KINS $15.21
- CYBN $6.63
- Average True Range (ATR)
- KINS 0.42
- CYBN 0.34
- MACD
- KINS 0.05
- CYBN 0.07
- Stochastic Oscillator
- KINS 62.40
- CYBN 46.71
About KINS Kingstone Companies Inc.
Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company. It offers insurance policies to small and mid-sized businesses as well as to individuals.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.